Which pharmacological treatment is indicated for pediatric patients with asthma?

Inhaled corticosteroids are considered the first-line pharmacological treatment for pediatric patients with asthma. They work by reducing inflammation in the airways, which is a key factor in asthma pathophysiology. Inhaled corticosteroids help to decrease the frequency and severity of asthma exacerbations and improve overall lung function.

This treatment is generally favored for long-term management as it allows for consistently controlled inflammation, leading to fewer symptoms and reduced reliance on rescue medications. Inhaled corticosteroids can also be used in conjunction with other treatments, enhancing overall disease management.

While leukotriene inhibitors, oral corticosteroids, and beta-agonists have specific roles in the treatment of asthma, they are not the primary choice for long-term management in pediatric patients. Leukotriene inhibitors can be useful but are considered a second-line option. Oral corticosteroids are typically used for short-term management during severe exacerbations rather than as a standard preventive measure. Beta-agonists, particularly short-acting options, serve as rescue medications for immediate symptom relief rather than a foundational treatment strategy. Thus, inhaled corticosteroids are the most appropriate first-line therapy for managing asthma in children.